Lv1
74 积分 2024-05-15 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
2天前
已完结
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial
2天前
已关闭
Ensartinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
2天前
已完结
Maximizing Adaptations in Concurrent Training: An Umbrella Review of Meta-analyses
7天前
已完结
Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR ‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study
8天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
8天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
8天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
9天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
9天前
已完结
皖公网安备34019202002308
